A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
- Sebastian M. Meyhöfer
- Bertrand Cariou
- Christoffer W. Tornøe
